Can diabetic nerve damage be reversed?
High levels of the protein p35 in activate a signaling pathway that limits nerve regrowth in diabetes.
A research team from the University of Cologne (Germany) has uncovered a key mechanism that explains why nerve regeneration is so limited in diabetes and unveiled a promising therapeutic approach to enhance nerve regrowth, offering hope for improved treatment options.
Nerve damage, or diabetic neuropathy, is a widespread and debilitating complication of diabetes that affects millions of people globally causing symptoms such as pain, numbness and limited movement. These symptoms arise because damaged nerve fibers fail to regenerate adequately, but the reasons behind this lack of regeneration have remained unclear until now.
Cell therapies for autoimmune diseases
In this podcast, Lindsay Davies, Chief Scientific Officer at NextCell Pharma (Stockholm, Sweden), breaks down the science behind NextCell’s mesenchymal stromal cell therapy for type 1 diabetes and explores how these cells could be applied to other autoimmune conditions.
Using mouse models of both type 1 and type 2 diabetes, the researchers uncovered a critical mechanism at play. They found that the nerve cells accumulate high levels of a protein called p35. This protein triggers the activation of an enzyme, setting off a signaling cascade that ultimately blocks the natural regrowth of nerve fibers. This blockage severely limits the nerves’ ability to regenerate.
By targeting this signaling pathway, using both genetic methods and pharmacological interventions, the researchers were able to remove the block. As a result, the nerve fibers in diabetic mice grew at rates comparable to those in healthy animals. Even more encouraging, this regeneration led to significant improvements in motor and sensory functions.
Dietmar Fischer, Professor of Pharmacology at the University of Cologne’s Faculty of Medicine, and Director of the Center for Pharmacology at University Hospital Cologne, said: “For the first time, our results show that diabetic nerve healing can be brought back to a level that compares with that of healthy animals if the excessive activation of the signaling pathway is inhibited. Even when diabetic neuropathy has already manifested, an improvement in regeneration occurs.”
A peptide developed and patented by Fischer’s research group shows particular promise, as it directly targets the root cause of the problem, paving the way for its potential development into a drug.
Overall, this study opens up new possibilities for treating and potentially preventing diabetic nerve damage, which is one of the most common and currently incurable complications of diabetes. By addressing the underlying cause of limited nerve regeneration, the research offers hope for improving the quality of life for millions of patients suffering from diabetic neuropathy.